{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"17.4","value":"9.4"},{"groupId":"OG001","lowerLimit":"-1.5","upperLimit":"13.6","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"Pain at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.6","upperLimit":"6.5","value":"-1.1"},{"groupId":"OG001","lowerLimit":"-8.0","upperLimit":"5.7","value":"-1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Pain at Day 134"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.3","upperLimit":"11.1","value":"2.9"},{"groupId":"OG001","lowerLimit":"-10.7","upperLimit":"4.7","value":"-3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"Speech at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.9","upperLimit":"5.3","value":"-2.8"},{"groupId":"OG001","lowerLimit":"-11.2","upperLimit":"3.6","value":"-3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Speech at Day 134"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.9","upperLimit":"16.1","value":"7.6"},{"groupId":"OG001","lowerLimit":"-4.6","upperLimit":"11.4","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"Swallowing at Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-12.4","upperLimit":"3.4","value":"-4.5"},{"groupId":"OG001","lowerLimit":"-8.7","upperLimit":"5.5","value":"-1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Swallowing at Day 134"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"description":"The EORTC QLQ-HN35 is designed to be used together with the core QLQ-C30. The recall period for the items in the module was \"the past week\". Items hn1 to hn30 were scored on 4 point Likert type categorical scales (\"not at all\", \"a little\", \"quite a bit\", \"very much\").Items hn31 to hn35 had a \"no/yes\" response format. The scores were transformed into 0 to 100 scales, with a high score implying a high level of symptoms. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG000","title":"Xevinapant +IMRT"},{"description":"Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle in combination with with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of placebo matched to Xevinapant from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG001","title":"Placebo +IMRT"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here,\"Overall Number of Participants Analyzed\" signifies the participants who were evaluable for this outcome measure and \"number analysed\" signifies participants at the specific categories.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 64 and End of treatment (Day 134)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN35) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}